We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.81B
AUM Growth
+$276M
Cap. Flow
-$211M
Cap. Flow %
-4.39%
Top 10 Hldgs %
49.94%
Holding
159
New
17
Increased
40
Reduced
75
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$87M
2
RVMD icon
Revolution Medicines
RVMD
+$38.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.8M
4
AKRO
Akero Therapeutics
AKRO
+$19.6M
5
IMCR icon
Immunocore
IMCR
+$12.1M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$93.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$78.5M
3
BPMC
Blueprint Medicines
BPMC
+$36.5M
4
MRNA icon
Moderna
MRNA
+$34.3M
5
SYK icon
Stryker
SYK
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Technology 0.03%
3 Consumer Discretionary 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAI
126
Caris Life Sciences
CAI
$4.39B
$291K 0.01%
9,605
-395
-4% -$12.6K
QURE icon
127
uniQure
QURE
$2.68B
$278K 0.01%
4,763
-14,847
-76% -$270K
BIDU icon
128
Baidu
BIDU
$35.8B
$264K 0.01%
2,000
– –
GOOGL icon
129
Alphabet (Google) Class A
GOOGL
$3.91T
$263K 0.01%
1,082
-368
-25% -$77.1K
MLTX icon
130
MoonLake Immunotherapeutics
MLTX
$1.59B
$251K 0.01%
35,052
+32,052
+1,068% +$1.67M
MRNA icon
131
Moderna
MRNA
$21.5B
$241K 0.01%
9,341
-1,229,327
-99% -$34.3M
KRYS icon
132
Krystal Biotech
KRYS
$9.88B
$232K ﹤0.01%
1,312
+62
+5% +$9.28K
ALKS icon
133
Alkermes
ALKS
$8.82B
$198K ﹤0.01%
+6,594
New +$186K
PTCT icon
134
PTC Therapeutics
PTCT
$6.37B
$155K ﹤0.01%
2,530
-1,270
-33% -$66.1K
NVDA icon
135
NVIDIA
NVDA
$5.01T
$131K ﹤0.01%
702
-49
-7% -$8.54K
ZTS icon
136
Zoetis
ZTS
$31.6B
$128K ﹤0.01%
872
+215
+33% +$32.5K
GH icon
137
Guardant Health
GH
$19.5B
$122K ﹤0.01%
+1,953
New +$106K
ORCL icon
138
Oracle
ORCL
$331B
$117K ﹤0.01%
417
-237
-36% -$60.4K
CYTK icon
139
Cytokinetics
CYTK
$11B
$115K ﹤0.01%
2,100
-1,641
-44% -$67.6K
MSFT icon
140
Microsoft
MSFT
$2.84T
$105K ﹤0.01%
203
– –
A icon
141
Agilent Technologies
A
$39.1B
$103K ﹤0.01%
806
– –
CORT icon
142
Corcept Therapeutics
CORT
$10.2B
$102K ﹤0.01%
+1,227
New +$88.8K
GMAB icon
143
Genmab
GMAB
$17.7B
$92.3K ﹤0.01%
+3,009
New +$73.3K
AMRX icon
144
Amneal Pharmaceuticals
AMRX
$5.72B
$79.2K ﹤0.01%
+7,913
New +$71K
MRUS
145
DELISTED
Merus
MRUS
$77.7K ﹤0.01%
825
-6,940
-89% -$452K
QCOM icon
146
Qualcomm
QCOM
$176B
$74.4K ﹤0.01%
447
– –
MTD icon
147
Mettler-Toledo International
MTD
$26.8B
$51.6K ﹤0.01%
42
– –
RXRX icon
148
Recursion Pharmaceuticals
RXRX
$1.57B
$26.9K ﹤0.01%
5,514
– –
ACLX
149
DELISTED
Arcellx
ACLX
– –
-3,000
Closed -$198K
ADMA icon
150
ADMA Biologics
ADMA
$1.92B
– –
-16,900
Closed -$308K
3 4 5
6
7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q3 2025 Portfolio in Review

As of Q3 2025, Bellevue Group held 159 positions worth $4.81B, up 6.1% from $4.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group withdrew a net $211M in Q3 2025, closing 11 positions and reducing 75 holdings. Its most notable exit was Blueprint Medicines, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Avidity Biosciences worth $93.8M.

  • Bellevue Group's largest Q3 2025 buy was Avidity Biosciences: 2,152,862 shares worth $93.8M.
  • Bellevue Group added most to Revolution Medicines in Q3 2025, an estimated $38.9M increase.
  • Bellevue Group's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $93.6M.
  • Bellevue Group fully exited Blueprint Medicines in Q3 2025, selling an estimated $36.5M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.81B portfolio in Q3 2025.
  • Bellevue Group opened 17 new positions and closed 11 in Q3 2025.
  • Bellevue Group's portfolio value rose 6.1% quarter-over-quarter to $4.81B.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.